Eric H Liu1, Carmen C Solorzano1, Laurence Katznelson2, Aaron I Vinik3, Richard Wong4, Gregory Randolph5. 1. Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University, Nashville, Tennessee. 2. Department of Medicine, Stanford University, Palo Alto, California. 3. Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Otolaryngology, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
OBJECTIVE: Neuroendocrine tumors (NETs) are a collection of complex tumors that arise from the diffuse endocrine system, primarily from the digestive tract. Carcinoid tumors most commonly originate from the small intestine. These tumors are either referred to as small intestinal neuroendocrine tumors or midgut carcinoids (MGCs). The purpose of this review article is to survey the diagnostic and therapeutic pathways for patients with MGC and provide an overview of the complex multidisciplinary care involved in improving their quality of life, treatment outcomes, and survival. METHODS: The current literature regarding the diagnosis and management of MGCs was reviewed. RESULTS: Dry flushing and secretory diarrhea are the hallmarks of the clinical syndrome of MGC. Managing MGC requires attention to the overall symptom complex, including the physical effects of the tumor and biomarker levels. The somatostatin analogs (SAs) octreotide and lanreotide are highly efficacious for symptomatic improvement. MGCs require resection to encompass the primary tumor and mesenteric lymph node metastases and should include cholecystectomy if the patient is likely to receive SA therapy. Debulking of liver metastasis by resection in combination with ablative therapies and other liver-directed modalities may help palliate symptoms and hormonal overproduction in carefully selected patients. Quality of life is an important measure of patients' perception of the burden of their disease and impact of treatment modalities and may be a useful guide in deciding changes in therapy to alter apparent health status. CONCLUSION: MGC is a challenging malignancy that requires the input of a multidisciplinary team to develop the best treatment plan. Consultation with expert centers that specialize in NETs may also be indicated for complex cases. With expert care, patients can be cured or live with the disease and enjoy good quality of life.
OBJECTIVE:Neuroendocrine tumors (NETs) are a collection of complex tumors that arise from the diffuse endocrine system, primarily from the digestive tract. Carcinoid tumors most commonly originate from the small intestine. These tumors are either referred to as small intestinal neuroendocrine tumors or midgut carcinoids (MGCs). The purpose of this review article is to survey the diagnostic and therapeutic pathways for patients with MGC and provide an overview of the complex multidisciplinary care involved in improving their quality of life, treatment outcomes, and survival. METHODS: The current literature regarding the diagnosis and management of MGCs was reviewed. RESULTS:Dry flushing and secretory diarrhea are the hallmarks of the clinical syndrome of MGC. Managing MGC requires attention to the overall symptom complex, including the physical effects of the tumor and biomarker levels. The somatostatin analogs (SAs) octreotide and lanreotide are highly efficacious for symptomatic improvement. MGCs require resection to encompass the primary tumor and mesenteric lymph node metastases and should include cholecystectomy if the patient is likely to receive SA therapy. Debulking of liver metastasis by resection in combination with ablative therapies and other liver-directed modalities may help palliate symptoms and hormonal overproduction in carefully selected patients. Quality of life is an important measure of patients' perception of the burden of their disease and impact of treatment modalities and may be a useful guide in deciding changes in therapy to alter apparent health status. CONCLUSION: MGC is a challenging malignancy that requires the input of a multidisciplinary team to develop the best treatment plan. Consultation with expert centers that specialize in NETs may also be indicated for complex cases. With expert care, patients can be cured or live with the disease and enjoy good quality of life.
Authors: Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057
Authors: Clarisse Dromain; Thierry de Baere; Jean Lumbroso; Hubert Caillet; Agnès Laplanche; Valerie Boige; Michel Ducreux; Pierre Duvillard; Dominique Elias; Martin Schlumberger; Robert Sigal; Eric Baudin Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: R L Stronge; G B Turner; B T Johnston; D R McCance; A McGinty; C C Patterson; J E S Ardill Journal: Ann Clin Biochem Date: 2008-09-09 Impact factor: 2.057
Authors: Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339
Authors: G B Turner; B T Johnston; D R McCance; A McGinty; R G P Watson; C C Patterson; J E S Ardill Journal: Gut Date: 2006-03-23 Impact factor: 23.059
Authors: A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri Journal: Eur J Nucl Med Date: 1998-10
Authors: George A Fisher; Edward M Wolin; Nilani Liyanage; Susan Pitman Lowenthal; Beloo Mirakhur; Rodney F Pommier; Montaser Shaheen; Aaron Vinik Journal: Oncologist Date: 2017-10-16
Authors: Lowell B Anthony; Matthew H Kulke; Martyn E Caplin; Emily Bergsland; Kjell Öberg; Marianne Pavel; Dieter Hörsch; Richard R P Warner; Thomas M O'Dorisio; Joseph S Dillon; Pablo Lapuerta; Kenneth Kassler-Taub; Wenjun Jiang Journal: Oncologist Date: 2019-01-16
Authors: R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano Journal: J Endocrinol Invest Date: 2022-08-30 Impact factor: 5.467
Authors: Mohid S Khan; Thomas Walter; Amy Buchanan-Hughes; Emma Worthington; Lucie Keeber; Marion Feuilly; Enrique Grande Journal: World J Gastroenterol Date: 2020-08-14 Impact factor: 5.742